697 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Concentrum Wealth Management

Concentrum Wealth Management acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 697 shares of the medical research company’s stock, valued at approximately $201,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC raised its position in Amgen by 111.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 989,061 shares of the medical research company’s stock worth $284,869,000 after acquiring an additional 522,367 shares during the last quarter. Natixis Advisors L.P. raised its position in Amgen by 7.3% during the fourth quarter. Natixis Advisors L.P. now owns 249,827 shares of the medical research company’s stock worth $71,955,000 after acquiring an additional 17,043 shares during the last quarter. Commonwealth Equity Services LLC raised its position in Amgen by 1.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 383,078 shares of the medical research company’s stock worth $110,334,000 after acquiring an additional 7,296 shares during the last quarter. Fisher Asset Management LLC raised its position in Amgen by 4.3% during the fourth quarter. Fisher Asset Management LLC now owns 78,929 shares of the medical research company’s stock worth $22,733,000 after acquiring an additional 3,225 shares during the last quarter. Finally, FFT Wealth Management LLC raised its position in Amgen by 5.8% during the fourth quarter. FFT Wealth Management LLC now owns 1,019 shares of the medical research company’s stock worth $293,000 after acquiring an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMGN. Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. UBS Group cut their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. The Goldman Sachs Group boosted their price objective on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. TD Cowen cut their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 price objective on shares of Amgen in a research report on Wednesday, April 3rd. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $297.40.

Amgen Stock Down 0.1 %

Shares of AMGN stock traded down $0.33 on Thursday, hitting $277.04. The stock had a trading volume of 1,254,057 shares, compared to its average volume of 2,791,824. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a market capitalization of $148.60 billion, a price-to-earnings ratio of 22.11, a P/E/G ratio of 2.65 and a beta of 0.60. The stock’s 50 day moving average is $274.64 and its 200-day moving average is $281.35.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the prior year, the firm posted $4.09 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.25%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.